Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus chemotherapy in EGFR-negative non-squamous NSCLC
ChiCTR-OPC-16009894Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: progression-free survival, objective response rate and 2 more. Started Nov 2016; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-16009894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16009894.